ArticleNature communications2022
The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma.
Registry-linked trialOpen access · goldAbstract read
In one paragraph
Article in Nature communications, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07695311 (Precision Analysis of Fusion Genes in Ewing Sarcoma), which is not on this map. Cited by 52 papers.
0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed
6.6field-weighted citation impact, top 2% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
NCT07695311 phase1not yet recruitingnot on this mapstarted 2026, after this paper: background citation
Precision Analysis of Fusion Genes in Ewing Sarcoma (ES) and Desmoplastic Small Round Cell Tumor (DSRCT), Then EWSR1 (Ewing Sarcoma Gene Breakpoint Region 1 Gene) Immunotherapy Without or With Anti-CTLA-4 (Botensilimab) and Anti-PD1 (Balstilimab)
Who cites it
52 citing papers in PubMed, 68 citations in OpenAlex.
- Warehouse-based, immunopeptidome-guided design of personalised peptide vaccines shows feasibility in clinical trial evaluation in CLL patients.Frontiers in immunology · 2024Trial
- Molecular biomarkers for diagnosis, prognosis, precision therapy, and immunotherapy in cholangiocarcinoma, cHCC-CCA, and HCC.Hepatology communications · 2026Review
- Fibrolamellar Carcinoma in the Molecular Era: From DNAJB1::PRKACA Biology to Precision Therapeutic Strategies.Journal of gastrointestinal cancer · 2026Review
- Vaccinating against the 'undruggable'-a new paradigm for fibrolamellar carcinoma.Hepatobiliary surgery and nutrition · 2026Article
- Clinical guideline for the diagnosis and treatment of fibrolamellar carcinoma.Hepatology (Baltimore, Md.) · 2026Article
- From Universal Aspiration to Precision Immunization: A Hypothesis Framework for Antigen-Defined, HLA-Restricted Cancer Vaccines.Vaccines · 2026Review
- Review
- Tumour endothelial cell reprogramming orchestrates angiocrine signalling to drive chemoresistance in breast cancer.Angiogenesis · 2026Article
- Functional Precision Oncology in Fibrolamellar Carcinoma: Ex Vivo Identification of Therapeutic Vulnerabilities.Cancers · 2026Article
- Neoantigen Targeting as a Novel Approach for Therapy-Resistant Tumors.Molecular diagnosis & therapy · 2026Review
- Overcoming CXCR4-Mediated T-Cell Exclusion Potentiates Antitumor Cytotoxicity in Fibrolamellar Carcinoma.Gastroenterology · 2026Article
- Natural products and dietary bioactives as antiviral agents against herpesviruses: molecular mechanisms, immunomodulatory actions, and nutritional perspectives.Archives of microbiology · 2026Review
- The GF-NEO discovery platform unveils a [KQE][DG] sequence motif within fusion neoantigens in pediatric cancer.iScience · 2026Article
- Metastatic Fibrolamellar Hepatocellular Carcinoma in a Young Adult: A Case Report and Narrative Review.Journal of hepatocellular carcinoma · 2026Article
- Peptide‑based therapeutics targeting the SLC39A14‑PIWIL2 fusion in hepatocellular carcinoma.Genomics & informatics · 2025Article
- Article
- Cancer Vaccines: Molecular Mechanisms, Clinical Progress, and Combination Immunotherapies with a Focus on Hepatocellular Carcinoma.Current issues in molecular biology · 2025Review
- Disease patterns and entities in adult liver consult cases highlight challenging areas in diagnostic hepatopathology practice.Virchows Archiv : an international journal of pathology · 2025Article
- A therapeutic peptide vaccine for fibrolamellar hepatocellular carcinoma: a phase 1 trial.Nature medicine · 2025Article
- mRNA Cancer Vaccines: From Pandemic Paradigm to Personalized Oncology Therapeutics.Cancer innovation · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 6 institutions in 1 country.
Jens BauerDepartment of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0003-3731-2385
Natalie KöhlerDepartment of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University, Freiburg, Germany.ORCID 0000-0002-7502-0431
Yacine MaringerDepartment of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-2197-8740
Philip BucherCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.ORCID 0000-0001-7951-1580
Tatjana BilichDepartment of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
Melissa ZwickDepartment of Internal Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, Albert Ludwigs University, Freiburg, Germany.
Severin DicksFaculty of Biology, Albert-Ludwigs-Universität, Freiburg, Germany.
Annika NeldeDepartment of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0001-8504-8481
Marissa DubbelaarDepartment of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-4930-1467
Jonas ScheidDepartment of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-5923-1343
Marcel WackerDepartment of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-8185-140X
Jonas S HeitmannCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Sarah SchroederDepartment of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
Jonas RiethDepartment of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
Monika DenkDepartment of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
Marion RichterDepartment of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany.
Reinhild KleinDepartment of Hematology, Oncology, Clinical Immunology and Rheumatology, University Hospital Tübingen, Tübingen, Germany.
Irina BonzheimDepartment of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany.ORCID 0000-0002-7732-0788
Julia LuibrandDepartment of Pathology and Neuropathology, University Hospital Tübingen, Tübingen, Germany.
Ursula HolzerDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tübingen, Tübingen, Germany.
Martin EbingerDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tübingen, Tübingen, Germany.ORCID 0000-0002-4229-8058
Ines B BrechtDepartment of Pediatric Hematology and Oncology, University Children's Hospital, University of Tübingen, Tübingen, Germany.
Michael BitzerCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Melanie BoerriesInstitute of Medical Bioinformatics and Systems Medicine, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Judith FeuchtCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Helmut R SalihCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.ORCID 0000-0002-6719-1847
Hans-Georg RammenseeDepartment of Immunology, Institute for Cell Biology, University of Tübingen, Tübingen, Germany.
Stephan HailfingerCluster of Excellence iFIT (EXC2180) "Image-Guided and Functionally Instructed Tumor Therapies", University of Tübingen, Tübingen, Germany.
Juliane S WalzDepartment of Peptide-based Immunotherapy, University and University Hospital Tübingen, Tübingen, Germany. juliane.walz@med.uni-tuebingen.de.ORCID 0000-0001-6404-7391
University of Tübingen · DEUniversity Children's Hospital Tübingen · DEGerman Cancer Research Center · DEUniversity of Freiburg · DEDeutschen Konsortium für Translationale Krebsforschung · DEUniversity Hospital Münster · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
The DNAJB1-PRKACA fusion transcript is the oncogenic driver in fibrolamellar hepatocellular carcinoma, a lethal disease lacking specific therapies. This study reports on the identification, characterization, and immunotherapeutic application of HLA-presented neoantigens specific for the DNAJB1-PRKACA fusion transcript in fibrolamellar hepatocellular carcinoma. DNAJB1-PRKACA-derived HLA class I and HLA class II ligands induce multifunctional cytotoxic CD8
Indexed as
Carcinoma, HepatocellularLiver NeoplasmsCyclic AMP-Dependent Protein Kinase Catalytic SubunitsGene Expression Regulation, NeoplasticHSP40 Heat-Shock ProteinsHumansImmunotherapyNeoplasm Recurrence, LocalOncogene Proteins, FusionPeptidesCyclic AMP-Dependent Protein Kinase Catalytic SubunitsDNAJB1 protein, humanHSP40 Heat-Shock ProteinsOncogene Proteins, FusionPeptidesPRKACA protein, human
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT07695311ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.